Uremic pruritus clinical and non-clinical studies, key companies, treatment evaluation, emerging therapies, treatment algorithms, and pipeline analysis | Sol-Gel Technologies Co., Ltd., Crystal Biotech Co., Ltd.
Uremic Pruritus Pipeline Insights, DelveInsight
As revealed by DelveInsight's analysis, the uremic pruritus pipeline contains at least two major companies actively working on developing novel treatments for uremic pruritus.
Overview of uremic pruritus:
Uremic pruritus (UP), also known as chronic kidney disease-associated pruritus (CKD-aP), is a prevalent and often distressing symptom in patients with advanced chronic kidney disease (CKD), especially those undergoing dialysis. It is characterized by persistent pruritus, often without an obvious dermatological cause, and can severely impair patients' quality of life. Although the exact cause is still unknown, it is thought to be related to the accumulation of uremic toxins due to systemic inflammation, metabolic imbalance, and renal dysfunction.
The main symptom is severe, persistent itch, which may occur anywhere on the body or may be localized to certain areas such as the back, arms, or face. The itch tends to be worse at night, disrupting sleep and causing fatigue. Although there may be no visible skin changes initially, chronic scratching can cause secondary lesions and skin thickening. Uremic pruritus is often accompanied by other CKD symptoms such as dry skin and muscle spasms.
The diagnosis is primarily clinical, based on the patient's history of CKD and persistent itching without any obvious cause. Through examination and testing, doctors will rule out other potential causes, such as allergies and skin disorders. There is currently no cure, but treatments aim to manage symptoms and improve the patient's quality of life. Approaches include optimizing dialysis to reduce uremic toxins, using topical emollients for dry skin, and administering antihistamines or gabapentinoids to reduce itching. Systemic treatments such as opioid receptor modulators (e.g., nalfurafine), corticosteroids, and phototherapy (narrowband UVB) may also reduce symptoms.
For a detailed report on uremic pruritus pipeline insights, please see: https://www.delveinsight.com/report-store/uremic-pruritus-pipeline-insight?utm_source=report&utm_medium=promotion&utm_campaign=hpr
Key Takeaways from the Uremia Pruritus Pipeline Report:
DelveInsight's uremia pipeline report highlights an active field, with more than two major companies working on developing multiple therapies for the treatment of uremia.
Key companies in the uremic pruritus space, including Qilu Pharmaceutical, are researching new drugs to improve treatment options.
Promising uremic pruritus treatments currently in development include QLG2198.
Recent advances in the uremic pruritus pipeline:
-
Lumosa Therapeutics is developing LT5001, a topical ointment containing dinalbuphine sebacate (DNS) intended for the relief of itch. DNS acts as a kappa-opioid receptor agonist and μ-opioid receptor antagonist to target itch without significant systemic absorption. This formulation offers a convenient option for patients.
-
of U.S. Food and Drug Administration-approved Diflucan, sold as Corsba, for the treatment of moderate to severe pruritus in adults undergoing hemodialysis. This approval marks the first FDA-approved treatment specifically for uremic pruritus, providing relief to patients who previously had limited options.
Uremic pruritus pipeline analysis:
This report provides valuable insights into:
-
Major companies involved in developing treatments for uremic pruritus.
-
In-depth analysis of therapeutic candidates across various stages of development, including early-, mid- and late-stage treatments.
-
Major companies involved in the development of targeted therapeutics with both active and inactive projects.
-
Discover new drugs based on development stage, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecule type.
-
A detailed analysis of collaborations (both corporate-corporate and corporate-academic), licensing agreements, and funding details that are likely to drive future advancements in the Uremic Pruritus market.
For a free sample page report on Uremic Pruritus Pipeline Insights, please visit: https://www.delveinsight.com/sample-request/uremic-pruritus-pipeline-insight?utm_source=report&utm_medium=promotion&utm_campaign=hpr
New drugs for uremic pruritus:
-
QLG2198: Qilu Pharmaceutical
Uremic pruritus companies:
At least two major companies are developing treatments for uremic pruritus.Qilu Pharmaceutical are candidates who are at the most advanced stages of development. Phase III。
DelveInsight's reports cover multiple products at various stages of clinical development.
-
Post-production(Phase III)
-
Mid-term products(Phase II)
-
Early Stage Products(Phase I)
-
Preclinical and discovery stage candidates
-
Discontinued and inactive candidates
The Uraemic Pruritus Pipeline report also offers therapeutic assessment of pipeline drugs based on:
-
Route of Administration (ROA): Products are categorized into intravenous, subcutaneous, oral, and intramuscular routes.
-
Molecular Type: They are classified into monoclonal antibodies, small molecules, and peptides.
For a detailed assessment of new Uremic Pruritus Treatments and key players, download the sample report. https://www.delveinsight.com/report-store/uremic-pruritus-pipeline-insight?utm_source=report&utm_medium=promotion&utm_campaign=hpr
Pipeline therapeutics evaluated for uremic pruritus include:
-
Evaluation of uremic pruritus by product type
-
Stages of uremic pruritus
-
Evaluation of uremic pruritus by route of administration
-
Evaluation of uremic pruritus by molecular type
Download the Uremic Pruritus sample report for a comprehensive understanding of the treatment market. https://www.delveinsight.com/sample-request/uremic-pruritus-pipeline-insight?utm_source=report&utm_medium=promotion&utm_campaign=hpr
table of contents
1. Introduction to the report
2. Executive Summary
3. Current treatment patterns for uremic pruritus
4. Uremic pruritus – A DelveInsight analytical perspective
5. Treatment evaluation
6. Uremic pruritus Late-stage product (Phase III)
7. Uremic pruritus mid-stage product (Phase II)
8. Early Stage Products (Phase I)
9. Preclinical and discovery stage products
10. Inactive Products
11. Dormant products
12. Discontinued Products for Uremic Pruritus
13. Uremic pruritus product profile
14. Major Companies in Uremic Pruritus
15. Main products of uremic pruritus
16. Inactive and Discontinued Products
17. Unmet Needs in Uremic Pruritus
18. Future outlook for uremic pruritus
19. Analyst review of uremic pruritus
20. Appendix
21. Reporting Methods
Contact Information:
Himanshu
hmason@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading business consultancy and market research firm focused on life sciences, supporting pharmaceutical companies by providing comprehensive end-to-end solutions to improve their business performance.
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian